Provided by Tiger Fintech (Singapore) Pte. Ltd.

Royalty Pharma plc

34.84
-0.4300-1.22%
Post-market: 34.860.0190+0.05%18:52 EDT
Volume:3.53M
Turnover:123.05M
Market Cap:14.68B
PE:14.21
High:35.38
Open:35.09
Low:34.72
Close:35.27
Loading ...

Royalty Pharma (NasdaqGS:RPRX) Declares US$0.22 Dividend for Q2 2025

Simply Wall St.
·
23 Apr

Royalty Pharma Keeps Dividend at $0.22 A Share, Payable June 10 to Shareholders of Record May 16

MT Newswires Live
·
22 Apr

Press Release: Royalty Pharma Declares Second Quarter 2025 Dividend

Dow Jones
·
22 Apr

BofA Adjusts Price Target on Royalty Pharma to $42 From $41

MT Newswires Live
·
21 Apr

Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

THOMSON REUTERS
·
18 Apr

Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

GlobeNewswire
·
18 Apr

S&P 500 Futures Decline In Premarket Trading; Essential Prop Realty Tr, Americold Realty Trust Lead

Dow Jones
·
09 Apr

Royalty Pharma appoints Biohaven CEO Vlad Coric to board

TIPRANKS
·
09 Apr

Royalty Pharma Appoints Vlad Coric, M.d. to the Company’s Board of Directors

THOMSON REUTERS
·
09 Apr

Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors

GlobeNewswire
·
09 Apr

Bank of America Securities Remains a Buy on Royalty Pharma (RPRX)

TIPRANKS
·
27 Mar

BRIEF-Royalty Pharma Announces Upcoming Investor Day

Reuters
·
27 Mar

Royalty Pharma Announces Upcoming Investor Day

THOMSON REUTERS
·
27 Mar

TD Cowen Reaffirms Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
27 Mar

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

StockStory
·
21 Mar

Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Simply Wall St.
·
19 Mar

Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025

Insider Monkey
·
24 Feb

Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition

TIPRANKS
·
13 Feb

BUZZ-Royalty Pharma falls after investing $250 mln in Biogen's lupus treatment

Reuters
·
12 Feb

Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D

MT Newswires Live
·
12 Feb